Common Allergic Reactions to Artesunate
Artesunate, an antimalarial drug derived from artemisinin, can trigger allergic responses ranging from mild to severe. These typically involve skin reactions like rash, itching (pruritus), or hives (urticaria). Other immediate symptoms include swelling of the face, lips, tongue, or throat (angioedema), which signals potential airway involvement.[1]
Severe Reactions Including Anaphylaxis
In rare cases, artesunate causes anaphylaxis, a life-threatening reaction. Symptoms start within minutes of administration (often intravenous) and include:
- Difficulty breathing or wheezing
- Rapid heartbeat or low blood pressure
- Nausea, vomiting, or abdominal pain
- Dizziness or fainting
- Severe swelling blocking airways
Case reports document anaphylaxis in 1 in 3,000 to 10,000 treatments, more common with repeated exposure.[2][3]
Why Reactions Occur and Risk Factors
Allergies stem from IgE-mediated hypersensitivity to artesunate or its impurities like dihydroartemisinin. Cross-reactivity exists with other artemisinins (e.g., artemether). Patients with prior exposure, asthma, or atopy face higher risks. Delayed reactions (hours to days later) may mimic serum sickness with fever, joint pain, and rash.[4]
What to Do If Symptoms Appear
Stop the drug immediately and seek emergency care for breathing issues or swelling. Treatment follows standard protocols: epinephrine for anaphylaxis, antihistamines or corticosteroids for milder cases. Skin testing isn't routine due to limited validation.[1][5]
How Common Are These and Prevention Steps
Allergic events are uncommon—less than 0.1% in large trials—but underreported in malaria-endemic areas. Premedication with antihistamines lacks strong evidence. Monitor closely during IV infusion, especially in non-immune patients.[2][6]
[1]: WHO Guidelines on Artemisinin-Based Combination Therapies
[2]: PubMed: Anaphylaxis to Artesunate Review
[3]: The Lancet Infectious Diseases: Safety of Injectable Artesunate
[4]: Journal of Allergy and Clinical Immunology: Artemisinin Hypersensitivity
[5]: CDC Yellow Book: Malaria Treatment
[6]: Clinical Infectious Diseases: Post-Marketing Surveillance of Artesunate